Persistent Erectile Dysfunction in Men Exposed to 5α-Reductase Inhibitors, Finasteride, or Dutasteride

March 2017 in “ PeerJ ”

Tina Kiguradze, William H. Temps, Paul R. Yarnold, John Cashy, Robert E. Brannigan, Beatrice Nardone, Giuseppe Micali, Dennis P. West, Steven M. Belknap

5α-reductase inhibitors finasteride dutasteride persistent erectile dysfunction PED erectile dysfunction ED low libido 5ARIs Propecia Avodart

From the encyclopedia

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Studysummary This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study found a link between persistent erectile dysfunction (PED) and the use of 5α-reductase inhibitors (5ARIs) finasteride and dutasteride. PED can persist for months or years after discontinuing the use of 5ARIs, and the incidence of PED is higher in men who use 5ARIs compared to those who do not. The risk was higher in those with a prior history of the condition, and longer exposure duration increased the risk of developing new ED and new low libido. Healthcare providers should inform patients of this potential risk.

View this study on peerj.com →

Discuss this study in the Community →

Research cited in this study

41 / 41 results

research Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss

50 citations , September 2016 in “The Journal of Clinical Endocrinology and Metabolism”

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

Risk of Erectile Dysfunction Associated with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population-Based Studies Using the Clinical Practice Research Datalink

research Risk of Erectile Dysfunction Associated with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population-Based Studies Using the Clinical Practice Research Datalink

30 citations , September 2016 in “BMJ”

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

research Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss

19 citations , September 2016 in “Pharmacotherapy”

This study found that the risk of persistent sexual dysfunction was higher in men who stopped using finasteride 1 mg compared to omeprazole users.

research Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review

32 citations , July 2016 in “PubMed”

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

research Long-Term Safety and Efficacy of Dutasteride in the Treatment of Male Patients with Androgenetic Alopecia

32 citations , February 2016 in “Journal of Dermatology”

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

An Observational Retrospective Evaluation of 79 Young Men with Long-Term Adverse Effects After Use of Finasteride Against Androgenetic Alopecia

research An Observational Retrospective Evaluation of 79 Young Men with Long-Term Adverse Effects After Use of Finasteride Against Androgenetic Alopecia

43 citations , January 2016 in “International Journal of Andrology”

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

research Adverse Effects of 5α-Reductase Inhibitors: What Do We Know, Don't Know, and Need to Know?

111 citations , August 2015 in “Reviews in Endocrine and Metabolic Disorders”

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study

69 citations , July 2015 in “Pharmacotherapy”

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

research Appropriateness of Oral Drugs for Long-Term Treatment of Lower Urinary Tract Symptoms in Older Persons: Results of a Systematic Literature Review and International Consensus Validation Process (LUTS-FORTA 2014)

111 citations , June 2015 in “Age and Ageing”

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men With Benign Prostatic Hyperplasia

research Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men With Benign Prostatic Hyperplasia

20 citations , June 2015 in “Hormone Molecular Biology and Clinical Investigation”

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

research Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-Analysis

44 citations , April 2015 in “PubMed”

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

research Finasteride and the Uncertainties of Establishing Harms

7 citations , April 2015 in “JAMA Dermatology”

This text does not provide any research findings or results from a study.

research Persistent Sexual Dysfunction and Depression in Finasteride Users for Male Pattern Hair Loss: A Serious Concern or Red Herring?

10 citations , December 2014 in “PubMed”

This review examines reports of prolonged sexual dysfunction and depression associated with finasteride for male pattern hair loss, concluding that significant biases exist and further rigorous trials are needed to assess risks.

research Androgen Levels and Semen Parameters Among Former Users of Finasteride With Persistent Sexual Adverse Effects

15 citations , September 2014 in “JAMA Dermatology”

This discussion highlights the use of minimal incision extraction for lipoma removal, noting that it is a favored technique among dermatologists due to its efficiency, despite some hesitance with larger lipomas.

research Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride

81 citations , June 2014 in “American Journal of Men's Health”

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

research Androgenetic Alopecia: An Evidence-Based Treatment Update

151 citations , May 2014 in “American Journal of Clinical Dermatology”

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

research Organic Causes of Erectile Dysfunction in Men Under 40

2152 citations , November 2013 in “Urologia Internationalis”

This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.

Long-Term Oral Administration of 5α-Reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged Rats

research Long-Term Oral Administration of 5α-Reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged Rats

34 citations , September 2013 in “Urology”

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

Neuroactive Steroid Levels Are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology

research Neuroactive Steroid Levels Are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology

73 citations , July 2013 in “The Journal of Sexual Medicine”

This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.

The Efficacy and Safety of 5α-Reductase Inhibitors in Androgenetic Alopecia: A Network Meta-Analysis and Benefit–Risk Assessment of Finasteride and Dutasteride

research The Efficacy and Safety of 5α-Reductase Inhibitors in Androgenetic Alopecia: A Network Meta-Analysis and Benefit–Risk Assessment of Finasteride and Dutasteride

66 citations , June 2013 in “Journal of Dermatological Treatment”

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

research Androgenetic Alopecia (Male Pattern Hair Loss) in the United States: What Treatments Should Primary Care Providers Recommend?

3 citations , May 2013 in “Journal of the American Association of Nurse Practitioners”

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

research Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review

35 citations , April 2013 in “Sexual medicine reviews”

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

research Clinical Biochemistry of Dihydrotestosterone

50 citations , February 2013 in “Annals of Clinical Biochemistry”

This review discusses the production, role, and measurement of dihydrotestosterone (DHT) in various disorders of sexual development but does not report new clinical results.

research Depressive Symptoms and Suicidal Thoughts Among Former Users of Finasteride With Persistent Sexual Side Effects

134 citations , August 2012 in “The Journal of Clinical Psychiatry”

This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.

research Persistent Sexual Side Effects of Finasteride: Could They Be Permanent?

112 citations , July 2012 in “The Journal of Sexual Medicine”

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

research Incomplete Recovery of Erectile Function in Rats After Discontinuation of Dual 5-Alpha Reductase Inhibitor Therapy

29 citations , July 2012 in “The Journal of Sexual Medicine”

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

research Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss

185 citations , March 2011 in “The Journal of Sexual Medicine”

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido, Erectile Dysfunction, and Depression in a Subset of Patients

research Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido, Erectile Dysfunction, and Depression in a Subset of Patients

223 citations , December 2010 in “The Journal of Sexual Medicine”

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

research Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

152 citations , October 2010 in “Archives of Dermatology”

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

research Finasteride 5mg and Sexual Side Effects: How Many Are Related to a Nocebo Phenomenon?

225 citations , July 2007 in “The Journal of Sexual Medicine”

In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.

research A New Look at the 5-Alpha-Reductase Inhibitor Finasteride

137 citations , March 2006 in “Cns Drug Reviews”

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

Evaluation of Sexual Function With an International Index of Erectile Function in Subjects Taking Finasteride for Androgenetic Alopecia

research Evaluation of Sexual Function With an International Index of Erectile Function in Subjects Taking Finasteride for Androgenetic Alopecia

44 citations , July 2004 in “Archives of Dermatology”

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

research Finasteride: Ten Years of Clinical Use. Systematic Literature Review

14 citations , January 2003 in “Actas Urológicas Españolas”

This review found strong evidence supporting Finasteride's effectiveness in reducing symptoms and improving quality of life in patients with larger prostate volumes, earning it a grade A recommendation for clinical use.

research Evaluation of Sexual Function in Subjects Taking Finasteride for the Treatment of Androgenetic Alopecia

36 citations , September 2001 in “Journal of The European Academy of Dermatology and Venereology”

This study found that sexual and erectile function in men taking finasteride 1 mg did not significantly differ from age-matched controls, suggesting sexual side effects may be less common than previously reported.

research The Effects of Finasteride on Scalp Skin and Serum Androgen Levels in Men with Androgenetic Alopecia

65 citations , October 1999 in “Journal of The American Academy of Dermatology”

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

research Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss

46 citations , October 1999 in “Journal of The American Academy of Dermatology”

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

research The Effects of Finasteride on Scalp Skin and Serum Androgen Levels in Men with Androgenetic Alopecia

12 citations , October 1999 in “Journal of The American Academy of Dermatology”

research Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss

5 citations , October 1999 in “Journal of The American Academy of Dermatology”

research The Clinical Development of a 5α-Reductase Inhibitor, Finasteride

211 citations , November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology”

Finasteride effectively treats BPH, but needs more trials to understand potential.

research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers

147 citations , April 1990 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

C19 and C21 5β/5α Metabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency

research C19 and C21 5β/5α Metabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency

55 citations , March 1990 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that finasteride decreased plasma dihydrotestosterone levels and altered steroid metabolism, similar to the profile of male pseudohermaphrodites with inherited 5a-reductase deficiency.